About Owkin
Owkin is building what it calls Biological Artificial Superintelligence—an autonomous AI scientist designed to automate biopharma research and development. The company's vision is a world where R&D is automated and research is directly connected to care, addressing the profound complexity of biology that exceeds the limits of human intelligence alone. Owkin's flagship product, K Pro, is an AI agent that connects research and care, continuously learning from real-world data, user feedback, and clinical validation. K Pro enables pharma companies to make data-driven decisions across the entire drug development pipeline—from target discovery and biomarker validation to patient stratification and clinical trial design. The platform is trained and validated on MOSAIC, Owkin's proprietary multimodal patient data network spanning multiple therapeutic areas and healthcare institutions across Europe and North America. This network provides deeply curated clinical data alongside spatial transcriptomics, single-cell RNA, bulk RNA, whole exome sequencing, and H&E pathology images. Owkin's AI is refined through wet lab infrastructure and a global network of leading oncologists and biologists, with findings fed back to continuously improve the AI scientist. The company has published over 70 papers in high-impact journals and partners with leading academic medical centers, pharma companies including Sanofi, and consulting firms. Owkin has also incubated Bioptimus (building foundation models for biology), spun out Waiv (AI-powered precision diagnostics), and sponsors clinical trials through its affiliate Epkin. With offices in Paris, London, New York, Geneva, Nantes, and Boston, Owkin is positioning itself at the forefront of agentic AI for drug discovery and development.
Mission & Story
Mission
Our vision is a world where R&D is automated and research is directly connected to care
Clinical Focus
Medical conditions and clinical areas addressed by Owkin.
Who It Serves
Milestones & Awards
Recent Milestones
Multi-year K Pro collaboration with Sanofi announced (June 2026), Rewiring Biology Hackathon (July 2026), K Pro Reports case study published (February 2026), partnerships with University Hospital Vienna and Newcastle NHS Trust, incubation of Bioptimus, spin-out of Waiv
Key Partnerships
Social & Media
Follow on
Latest Updates
A Practical Map of Evaluation for Agentic SystemsJuly 6, 2026
2w ago
After the Decision: The Hard Work of Making AI Work in BiologyJuly 3, 2026
2w ago
Claude and K Pro - cracking biology togetherJune 30, 2026
3w ago
Why Targeting Prostaglandin Signalling Reawakens the Entire Antitumor Immune ResponseJune 26, 2026
3w ago
Benchmarking Biology: How Owkin is deepening its collaboration with NVIDIA towards the next frontier of Biological Artificial Super IntelligenceJune 23, 2026
4w ago
Company Details
- Headquarters
- Paris, France
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.